AMGEN INC is 11.3x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($183.41 B vs $16.17 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NBIX | AMGN |
|---|---|---|
| Market cap | $16.17 B | $183.41 B |
| US-listed rank | #700 | #79 |
| Revenue (latest FY) | $2.86B | $36.75B |
| Net income (latest FY) | $478.60M | $7.71B |
| Net margin | 16.7% | 21.0% |
| P/E (trailing FY) | 33.8 | 23.8 |
| SEC filings | 2,097 | 1,011 |
AMGEN INC is 11.3x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($183.41 B vs $16.17 B).
In their latest fiscal years, NEUROCRINE BIOSCIENCES INC reported $2.86B in revenue while AMGEN INC reported $36.75B.
Full pages: NEUROCRINE BIOSCIENCES INC and AMGEN INC, or browse the full rankings.